Abstract: A photoacoustic sensor (100) is capable of detecting a predefined target gas in an area (Um). A process is capable of detecting the target gas with the use of such a sensor (100). A sample chamber (3) holds a gas sample (Gp) to be tested. Electromagnetic waves (eW) from a radiation source (1) pass through the sample chamber (3) and the detection chamber (4). The waves elicit in the detection chamber (4) an acoustic effect, which is measured by an acoustic sensor (7). The acoustic effect is correlated with the concentration of the target gas in the sample chamber (3). The detection chamber (4) is fluid-tightly sealed, is free from target gas and is filled with a replacement gas (Eg). The transmission of the replacement gas (Eg) has a spectral response similar to that of the transmission of the target gas in a predefined target gas wavelength range.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A device (1) for determining the concentration of a gas component is configured with a radiation source (30) for radiating (31) light as a light emission in an infrared wavelength range. Two detector arrays (52, 62) with two detector elements (50, 60) are configured suitably for detecting the light emission generated by the radiation source (30) in two detector arrays (52, 62). Two filter elements (51, 61) are associated with the detector elements (50, 60). The two detector elements (50, 60) are oriented in relation to the radiation source, so that a range of overlap (65) is obtained due to the two detector arrays (52, 62). The range of overlap (65) causes attenuations in the propagation of light, which may be due to gas molecules or moisture (400). The attenuations in the propagation of light affect both detector elements (50, 60) and are compensated concerning the determination of the concentration.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A device (1) for determining the concentration of a gas component is configured with a radiation source (30) for emitting (31) a light radiation or heat radiation in an infrared wavelength range. A detector array (40) has at least two detector elements (50, 60), configured to detect the radiation generated by the radiation source (30), in an angular arrangement (52, 62) and with filter elements (51, 61). At least one of the two detector elements (50, 60) is oriented in an angular arrangement (52, 62) in relation to a vertical axis (32), so that a range of overlap (65) is obtained due to the angular arrangements (52, 62). The range of overlap (65) causes attenuations in the propagation of light, which attenuations may be due, for example, to gas molecules or moisture (400), affect both detector elements (50, 60) and are thus compensated concerning the concentration determination.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: Described is a system and method for detecting contaminants using a flexible Surface Enhanced Raman Spectroscopy (SERS) substrate. The contaminant is collected on a flexible SERS substrate and directly interrogated with a Raman Spectrometer to obtaining a SERS emission spectrum for the contaminant. The obtained spectrum can be compared to a library of SERS signatures to identify the contaminant.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.